IQVIA Life Science Models were introduced at TechIQ 2026 to help life sciences companies predict clinical trial outcomes. IQVIA reports that 85% of predictions across 50 trials and 270 endpoints were on target or clinically close.
AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo and Anthropic announced a September 16, 2026 collaboration pairing Claude Science with Novo’s R&D teams to tackle drug discovery challenges and strengthen AI-driven software engineering, with financial terms undisclosed.
IQVIA has launched IQVIA Predictive Clinical Development, an AI-powered platform built with Anthropic, AWS, Databricks, Microsoft, NVIDIA, Palantir and Snowflake, designed to help sponsors bring new therapies to market up to two years faster.
For the best possible care, ultra-rare illnesses need both sophisticated genetic tests and diverse clinical competence.
Researchers demonstrated that these substances could eradicate methicillin-resistant Staphylococcus aureus.
